Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO ® ) Annual Meeting, taking place ...

Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company headquartered in New York. It researches, develops, and manufactures biopharmaceutical products for use in the ...

Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

The reversal from the Advisory Committee on Immunization Practices (ACIP) is a potential boost for GSK and Pfizer. Both companies saw sales of their RSV vaccines for adults tumble last year after ...

Dr Chris Boshoff, Pfizer's Chief Scientific Officer, confirmed in statement on April 14: 'While we are disappointed to discontinue the development of danuglipron, we remain committed to ...

The actor's bold tattoo appeared to be covered in black ink in new photos from the set Eric Charbonneau/Amazon MGM Studios via Getty; BACKGRID Ben Affleck's back tattoo looks a little ...

Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

open image in gallery Drugmaker Pfizer announced its decision to discontinue the development of its potential once-daily pill treatment for obesity, known as danuglipron. The decision came after a ...

Pfizer has ended its development of danuglipron, its oral weight-loss drug. (Image Credits: Reuters) Pfizer said on Monday it has discontinued development of experimental weight-loss pill ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury. The drugmaker Pfizer is ...